Switch theme
Sign up to access all valuation multiples
NRGene Technologies Ltd is engaged in the development of artificial intelligence-based software for the analysis of genetic information in order to improve species of plants and animals.
n/a
LTM Revenue n/a
LTM EBITDA n/a
$9.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
NRGene has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, NRGene achieved revenue of $0.3M and an EBITDA of -$0.7M.
NRGene expects next 12-month revenue of XXX and NTM EBITDA of XXX
See NRGene valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $0.5M | $0.3M | XXX | XXX | XXX |
| Gross Profit | $0.5M | $0.2M | XXX | XXX | XXX |
| Gross Margin | 86% | 70% | XXX | XXX | XXX |
| EBITDA | -$1.2M | -$0.7M | XXX | XXX | XXX |
| EBITDA Margin | -227% | -209% | XXX | XXX | XXX |
| Net Profit | -$1.7M | -$1.4M | XXX | XXX | XXX |
| Net Margin | -310% | -406% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, NRGene's stock price is ILS 3 (or $1).
NRGene has current market cap of ILS 38.8M (or $10.5M), and EV of ILS 34.8M (or $9.4M).
See NRGene trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $9.4M | $10.5M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, NRGene has market cap of $10.5M and EV of $9.4M.
NRGene's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate NRGene's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for NRGene and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $9.4M | XXX | XXX | XXX |
| EV/Revenue | 27.0x | XXX | XXX | XXX |
| EV/EBITDA | -12.9x | XXX | XXX | XXX |
| P/E | -11.6x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -6.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpNRGene's NTM/LTM revenue growth is n/a
NRGene's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, NRGene's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate NRGene's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for NRGene and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -36% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -209% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -41% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 11% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 53% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 140% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 367% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Presight AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Pointerra | XXX | XXX | XXX | XXX | XXX | XXX |
| Beamtree | XXX | XXX | XXX | XXX | XXX | XXX |
| Unith | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
NRGene acquired XXX companies to date.
Last acquisition by NRGene was XXXXXXXX, XXXXX XXXXX XXXXXX . NRGene acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| Where is NRGene headquartered? | NRGene is headquartered in Israel. |
| Is NRGene publicy listed? | Yes, NRGene is a public company listed on TAE. |
| What is the stock symbol of NRGene? | NRGene trades under NRGN ticker. |
| When did NRGene go public? | NRGene went public in 2021. |
| Who are competitors of NRGene? | Similar companies to NRGene include e.g. Presight AI, Benevolent AI, Pointerra, Beamtree. |
| What is the current market cap of NRGene? | NRGene's current market cap is $10.5M |
| What is the current revenue growth of NRGene? | NRGene revenue growth between 2023 and 2024 was -36%. |
| Is NRGene profitable? | Yes, NRGene is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
